Update: Preclinical developments of the treatment of pulmonary arterial hypertension;Update: Präklinische Entwicklungen zur therapie der pulmonalen arteriellen Hypertonie

Deutsche Medizinische Wochenschrift

Volumn 134, Issue SUPPL. 5, 2009, Pages

  Janssen, W ^a   Ghofrani, H A ^b   Weissmann, N ^a,b   Grimminger, F ^b   Schermuly, R T ^a,b  

^a MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

Pulmonary arterial hypertension; Vascular emodeling; Vasoconstriction

Indexed keywords

ENDOTHELIN RECEPTOR ANTAGONIST; FASUDIL; IMATINIB; PHOSPHODIESTERASE V INHIBITOR; PROSTANOID; SIMVASTATIN; ENDOTHELIN RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PANCREATIC ELASTASE; PHOSPHODIESTERASE I; PHOSPHODIESTERASE V; PROSTACYCLIN; PROTEIN TYROSINE KINASE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RHO KINASE; SEROTONIN ANTAGONIST; VASODILATOR AGENT;

BLOOD VESSEL TONE; BLOOD VESSEL WALL; DISEASE COURSE; HUMAN; LUNG ALVEOLUS CELL; PULMONARY ARTERY; PULMONARY HYPERTENSION; REVIEW; VASOCONSTRICTION; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; DISEASE PROGRESSION; EPOPROSTENOL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION, PULMONARY; NADPH OXIDASE; PANCREATIC ELASTASE; PHOSPHODIESTERASE I; PROTEIN-TYROSINE KINASES; PULMONARY ARTERY; REACTIVE OXYGEN SPECIES; RECEPTORS, ENDOTHELIN; RHO-ASSOCIATED KINASES; SEROTONIN ANTAGONISTS; SIGNAL TRANSDUCTION; VASOCONSTRICTION; VASODILATOR AGENTS;

EID: 70349315225     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0029-1225313     Document Type: Review

References (17)

1. Abe K, Shimokawa H, Morikawa K et al. Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ Res 2004; 94: 385-393
2. Cowan K, Heilbut A, Humpl T, Lam C, Ito S, Rabinovitch M. Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor. Nat Med 2000; 6: 698-702
3. Dumitrascu R, Weissmann N, Ghofrani HA et al. Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling. Circulation 2006; 113: 286-295
4. Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 2005; 353: 1412-1413 (Pubitemid 41362714)
5. Girgis RE, Mozammel S, Champion HC et al. Regression of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Lung Cell Mol Physiol 2007; 292: L1105-1110
6. Guignabert C et al. Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats. Circulation 2005; 111: 2812-2819
7. Ishikura K, Yamada N, Ito M et al. Beneficial acute effects of Rho-kinase inhibitor in patients with pulmonary arterial hypertension. Circ J 2006; 70: 174-178
8. Kao PN. Simvastatin treatment of pulmonary hypertension: an observational case series. Chest 2005; 127: 1446-1452
9. Klein M, Schermuly RT, Ellinghaus P et al. Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling. Circulation 2008; 118: 2081-2090
10. Mittal M, Roth M, König P et al. Hypoxia-dependent regulation of nonphagocytic NADPH oxidase subunit NOX4 in the pulmonary vasculature. Circ Res 2007; 101: 258-267
11. Murray F, Patel HH, Suda RY et al. Expression and activity of cAMP phosphodiesterase isoforms in pulmonary artery smooth muscle cells from patients with pulmonary hypertension: role for PDE 1. Am J Physiol Lung Cell Mol Physiol 2007; 292: L294-L303
12. Patterson KC, Weissmann A, Ahmadi T, Farber HW. Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension. Ann Intern Med 2006; 145: 152-153
13. Rabinovitch M. Elstase and the pathobiology of unexplained pulmonary hypertension. Chest 1998 114 (3 Suppl.) 213S-224S
14. Schermuly RT, Dony E, Ghofrani HA et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005; 115: 2811-2821
15. Schermuly RT, Pullamsetti SS, Kwapiszeswka G et al. Phosphodiesterase 1 upregulation in pulmonary arterial hypertension: target for reverse-remodeling therapy. Circulation 2007; 115: 2331-2339
16. Schermuly RT, Stasch JP, Pullamsetti PA et al. Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. Eur Respir J 2008; 32: 881-891
17. Souza R, Sitbon O, Parent F, Simonneau G, Humbert M. Long term imatinib treatment in pulmonary arterial hypertension. Thorax 2006 61 736-736